SAL0140 placebo

DRUG3 trials

Sponsors

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Conditions

Chronic Kidney DiseasePrimary AldosteronismUncontrolled Hypertension

Phase 1

SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population

RecruitingNCT07051603

Shenzhen Salubris Pharmaceuticals Co., Ltd.Uncontrolled Hypertension

Start: 2025-06-09End: 2026-02-28Target: 82Updated: 2025-07-04

Phase 2

A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism

Not yet recruitingNCT07646535

Shenzhen Salubris Pharmaceuticals Co., Ltd.Primary Aldosteronism

Start: 2026-06-12End: 2027-12-31Target: 50Updated: 2026-06-12

A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease

Not yet recruitingNCT07647133

Shenzhen Salubris Pharmaceuticals Co., Ltd.Chronic Kidney Disease

Start: 2026-06-15End: 2027-12-31Target: 249Updated: 2026-06-15